Saltar al contenido
Merck

W266418

(S)-(−)-Perillyl alcohol

≥95%, FG

Sinónimos:

p-Mentha-1,8-diene-7-ol

Iniciar sesión para ver los precios por organización y contrato.

Seleccione un Tamaño

Cambiar Vistas

Acerca de este artículo

Fórmula empírica (notación de Hill):
C10H16O
Número CAS:
Peso molecular:
152.23
FEMA Number:
2664
Council of Europe no.:
2024
UNSPSC Code:
12164502
PubChem Substance ID:
Flavis number:
2.060
NACRES:
NA.21
MDL number:
Organoleptic:
fatty; green
Grade:
FG, Halal, Kosher
Biological source:
synthetic
Food allergen:
no known allergens
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarle


biological source

synthetic

Quality Level

grade

FG, Halal, Kosher

reg. compliance

EU Regulation 1334/2008 & 178/2002, FDA 21 CFR 117, FDA 21 CFR 172.515

assay

≥95%

optical activity

[α]20/D −88°, c = 1 in methanol

refractive index

n20/D 1.501 (lit.)

bp

119-121 °C/11 mmHg (lit.)

density

0.96 g/mL at 25 °C (lit.)

application(s)

flavors and fragrances

documentation

see Safety & Documentation for available documents

food allergen

no known allergens

organoleptic

fatty; green

SMILES string

CC(=C)[C@H]1CCC(CO)=CC1

InChI

1S/C10H16O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,10-11H,1,4-7H2,2H3/t10-/m1/s1

InChI key

NDTYTMIUWGWIMO-SNVBAGLBSA-N

Application


  • CYP108N12 initiates p-cymene biodegradation in Rhodococcus globerulus.: This study explores the enzymatic breakdown pathways of monoterpenes, using (S)-(−)-Perillyl alcohol as a precursor, offering insights into microbial degradation processes that could be vital for bioremediation efforts or synthetic biology applications (Giang et al., 2022).

  • Orofacial antinociceptive effects of perillyl alcohol associated with codeine and its possible modes of action.: Research demonstrates the pain-relieving properties of (S)-(−)-Perillyl alcohol when combined with codeine, highlighting its potential for developing new analgesic formulations in dental and facial pain management (Limeira et al., 2022).

  • Orofacial antinociceptive activity of (S)-(-)-perillyl alcohol in mice: a randomized, controlled and triple-blind study.: This study underpins the effectiveness of (S)-(−)-Perillyl alcohol in reducing orofacial pain in a controlled experimental setup, providing a basis for further clinical trials in pain management (Tomaz-Morais et al., 2017).

  • In Vivo Anti-Tumor Activity and Toxicological Evaluations of Perillaldehyde 8,9-Epoxide, a Derivative of Perillyl Alcohol.: Highlights the anti-tumor properties of a novel derivative of (S)-(−)-Perillyl alcohol, suggesting its potential as a therapeutic agent in oncology, with comprehensive studies on its efficacy and safety (Andrade et al., 2016).



Still not finding the right product?

Explore all of our products under


pictograms

Exclamation mark

signalword

Warning

Hazard Classifications

Eye Irrit. 2 - Skin Irrit. 2 - STOT SE 3

target_organs

Respiratory system

Clase de almacenamiento

10 - Combustible liquids

wgk

WGK 3

flash_point_f

230.0 °F - closed cup

flash_point_c

110 °C - closed cup

ppe

Eyeshields, Gloves, type ABEK (EN14387) respirator filter



Elija entre una de las versiones más recientes:

Certificados de análisis (COA)

Lot/Batch Number

¿No ve la versión correcta?

Si necesita una versión concreta, puede buscar un certificado específico por el número de lote.

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos



Mohammad Farazuddin et al.
International journal of nanomedicine, 7, 35-47 (2012-01-26)
In the present study, a novel poly-lactic glycolic acid (PLGA)-based microparticle formulation of perillyl alcohol (POH) was prepared and characterized. Further, its efficacy was evaluated against di-methyl benzo anthracene-induced skin papilloma in Swiss albino mice. The characterization studies showed that
Hyun Joo Jung et al.
Blood, 119(11), 2568-2578 (2012-02-02)
Although bortezomib is clinically approved for the treatment of mantle cell lymphoma (MCL), only limited effects of this treatment have been demonstrated. To improve survival for bortezomib-resistant patients, it is necessary to develop new therapeutic strategies. In the present study
Laxmi Yeruva et al.
Anti-cancer drugs, 21(1), 1-9 (2009-10-13)
Breast cancer is the second leading cause of cancer deaths among women in the United States. Several treatment options exist, with different side effects. To alleviate the side effects, several research groups have studied chemotherapeutic effects of plant compounds on